Neutral macrocyclic factor VIIa inhibitors.

Area of Science:

• Biochemistry
• Pharmacology
• Medicinal Chemistry

Background:

• Factor VIIa (FVIIa) inhibitors demonstrate significant antithrombotic potential in preclinical models.
• Limited success in developing orally active FVIIa inhibitors is attributed to the need for a basic P1 group, hindering membrane permeability.
• Asp189 in the S1 binding pocket requires a basic P1 group for interaction, posing a challenge for oral drug design.

Purpose of the Study:

• To develop potent, orally active Factor VIIa (FVIIa) inhibitors with enhanced membrane permeability.
• To overcome the limitations of previous FVIIa inhibitor designs that required a basic P1 group.
• To combine neutral P1 binding substituents with an optimized macrocyclic chemotype.

Main Methods:

• Integration of recently reported neutral P1 binding substituents.
• Utilization of a highly optimized macrocyclic chemotype.
• Synthesis and evaluation of novel FVIIa inhibitor compounds.

Main Results:

• Achieved low nanomolar potency for the developed FVIIa inhibitors.
• Demonstrated enhanced permeability characteristics of the novel compounds.
• Successfully combined neutral P1 substituents with a macrocyclic core to yield potent inhibitors.

Conclusions:

• The developed FVIIa inhibitors exhibit promising antithrombotic efficacy and oral bioavailability.
• The strategy of using neutral P1 substituents overcomes previous permeability barriers.
• These findings pave the way for orally active anticoagulants targeting Factor VIIa.